News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. (LUN.CO) Release: Vortioxetine Clinical Phase III Data Show Significant Improvement in Symptoms of Major Depression


5/20/2013 10:00:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Valby, Denmark, 18 May 2013 - H. Lundbeck A/S (Lundbeck) and partner Takeda Pharmaceutical Company Limited (Takeda) today announced that the companies will be presenting new data on four pivotal studies on vortioxetine, a novel investigational drug under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of major depression. The phase III data will be presented at the 2013 Annual Meeting of the American Psychiatric Association (APA) in San Francisco, USA.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES